Alterity Therapeutics Limited

ALTERITY THERAPEUTICS LTD is a development stage medical biotechnology company. The company is currently focused on research activities and has not yet commercialized any products. Since its inception, ALTERITY THERAPEUTICS LTD has experienced recurring losses. For the year ended June 30, 2026, the company reported a net loss of $23,400,949, compared to a net loss of $12,147,828 in the year ended June 30, 2025. The net operating cash outflow for the year ended June 30, 2026, was $22,523,333, compared to $11,451,248 in the year ended June 30, 2025. The company's primary expenses are related to research and development (R&D) and general and administration. R&D expenses mainly cover activities conducted by third parties on behalf of ALTERITY THERAPEUTICS LTD. These expenses also include costs for acquiring and developing patents, as well as salaries and fees for employees and consultants involved in R&D. During the 2026 financial year, ALTERITY THERAPEUTICS LTD successfully raised new equity funding to support its planned R&D programs for at least the next 12 months.